St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN Multi-Electrode Renal...
Boston Scientific Corporation reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with...
June 3, 2013 — St. Jude Medical Inc. announced the company’s EnligHTN multi-electrode renal denervation system provides a safe, rapid and sustained reduction in blood pressure...
Kona Medical announced three and six month results from the WAVE I study, a first-in-man study evaluating the safety and efficacy of Kona Medical’s Surround Sound Renal Denervation System for...
Cardiosonic Inc. announced the completion of the first phase of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and...
Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension.
Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) have accepted the inclusion of the Symplicity renal denervation system...
St. Jude Medical Inc. announced plans for a new landmark study that will evaluate whether renal denervation and medication can provide health benefits to patients beyond lowering high blood...
St. Jude Medical Inc. announced enrollment of the first patient in the EnligHTN II trial. This post-market clinical study will further evaluate the safety and efficacy of the EnligHTN renal...
My job as editor of DAIC is to help readers keep tabs on the latest in cardiovascular technology and trends. With collaboration from my Editorial Advisory Board, we developed a...
To help identify trends and find out what DAIC readers are interested in, the magazine takes note of what they click on when visiting the website. Below are the top 25 stories from 2012, and the...
Covidien began the commercial launch of the OneShot Renal Denervation System, an over the wire balloon-based irrigated ablation catheter technology for the treatment of hypertension...
Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top...
December 27, 2012 — Cardiosonic Inc., a private developer of technology in the field of renal denervation for the treatment of hypertension, announced it has closed on the first $6.1 million of a...
The annual Transcatheter Cardiovascular Therapeutics (TCT) meeting brings many cutting-edge technologies to the forefront during its five days of clinical sessions. This is my editor’s choice of...
St. Jude Medical Inc. announced that the company’s EnligHTN renal denervation system provides a safe, effective and sustained reduction in office and ambulatory blood pressure measurements at six...
October 3, 2012 — Sharp Memorial Hospital was the first on the West Coast to participate in Medtronic's SYMPLICITY HTN-3 clinical trial in March, and is currently the leading trial site in ...
June 1, 2012 — Kona Medical Inc. announced it has raised $30 million in Series C financing to advance its novel hypertension therapy. Existing investors Essex Woodlands,...
May 18, 2012 -- St. Jude Medical Inc., a global medical device company, announced that preliminary data demonstrated the company’s EnligHTN renal denervation system was safe and effective for the...
May 15, 2012 – St. Jude Medical Inc., a global medical device company, announced CE mark approval and launch of its EnligHTN renal denervation system during EuroPCR. Renal denervation is a...
May 9, 2012 — Sound Interventions Inc. announced the successful completion of the company's first-in-human clinical trial to treat resistant hypertension, SOUND-ITV.
May 4, 2012 - Medtronic Inc. announced six-month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity renal...
May 2, 2012 — Vessix Vascular Inc. announced this week that it has received CE mark approval for its V2 Renal Denervation System for the treatment of hypertension. Renal denervation is a...
ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked Paradise (percutaneous renal denervation system) ultrasound platform, which is...
April 4, 2012 — Medtronic Inc. announced that the Symplicity renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment...
February 29, 2012 — Vessix Vascular Inc. announced initial patient treatments in the international multi-center Reduce-HTN renal denervation clinical study for uncontrolled hypertension.
February 20, 2012 — ReCor Medical announced that its Paradise percutaneous ultrasound renal denervation system for achieving rhas received the CE mark. Paradise is designed to treat patients with...
February 15, 2012 — Vessix Vascular Inc., developer of a novel percutaneous radiofrequency (RF) balloon catheter technology, announced that it will make its first detailed public presentation of...
February 15, 2012 — Medtronic Inc. announced the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s Symplicity renal denervation system across...
October 26, 2011 — Medtronic Inc. announced the start of SYMPLICITY HTN-3, the company’s United States clinical trial of the Symplicity Renal Denervation System for treatment-resistant...
March 30, 2011 – Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation, or RDN. RDN is a procedure that uses a catheter-based...
